Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
OtherTheranostics

Radiation Dosimetry in 177Lu-PSMA-617 Therapy Using a Single Post-treatment SPECT/CT: A Novel Methodology to Generate Time- and Tissue-specific Dose Factors

Price A Jackson, Michael S Hofman, Rodney J. Hicks, Mark Scalzo and John A Violet
Journal of Nuclear Medicine December 2019, jnumed.119.233411; DOI: https://doi.org/10.2967/jnumed.119.233411
Price A Jackson
Peter MacCallum Cancer Centre, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael S Hofman
Peter MacCallum Cancer Centre, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rodney J. Hicks
Peter MacCallum Cancer Centre, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Scalzo
Peter MacCallum Cancer Centre, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John A Violet
Peter MacCallum Cancer Centre, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

jnumed.119.233411
DOI 
https://doi.org/10.2967/jnumed.119.233411
PubMed 
31806772

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online December 5, 2019.

Article Versions

  • You are currently viewing a previous version of this article (December 5, 2019 - 10:37).
  • View the most recent version of this article
Copyright & Usage 
Copyright © 2019 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Author Information

  1. Price A Jackson,
  2. Michael S Hofman,
  3. Rodney J. Hicks,
  4. Mark Scalzo and
  5. John A Violet
  1. Peter MacCallum Cancer Centre, Australia
  1. For correspondence or reprints contact: Price A. Jackson, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC 3000, Australia. E-mail: price.jackson@petermac.org

Statistics from Altmetric.com

Cited By...

  • 91 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
    Katarina Sjögreen Gleisner, Nicolas Chouin, Pablo Minguez Gabina, Francesco Cicone, Silvano Gnesin, Caroline Stokke, Mark Konijnenberg, Marta Cremonesi, Frederik A. Verburg, Peter Bernhardt, Uta Eberlein, Jonathan Gear
    European Journal of Nuclear Medicine and Molecular Imaging 2022 49 6
  • Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
    Clemens Kratochwil, Wolfgang P. Fendler, Matthias Eiber, Michael S. Hofman, Louise Emmett, Jeremie Calais, Joseph R. Osborne, Amir Iravani, Phillip Koo, Liza Lindenberg, Richard P. Baum, Murat Fani Bozkurt, Roberto C. Delgado Bolton, Samer Ezziddin, Flavio Forrer, Rodney J. Hicks, Thomas A. Hope, Levent Kabasakal, Mark Konijnenberg, Klaus Kopka, Michael Lassmann, Felix M. Mottaghy, Wim J. G. Oyen, Kambiz Rahbar, Heiko Schoder, Irene Virgolini, Lisa Bodei, Stefano Fanti, Uwe Haberkorn, Ken Hermann
    European Journal of Nuclear Medicine and Molecular Imaging 2023 50 9
  • Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA I&T and 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry
    Christiane Schuchardt, Jingjing Zhang, Harshad R. Kulkarni, Xiaoyuan Chen, Dirk Müller, Richard P. Baum
    Journal of Nuclear Medicine 2022 63 8
  • ICRU REPORT 96, Dosimetry-Guided Radiopharmaceutical Therapy
    George Sgouros, Wesley E. Bolch, Arturo Chiti, Yuni K. Dewaraja, Dimitris Emfietzoglou, Robert F. Hobbs, Mark Konijnenberg, Katarina Sjögreen-Gleisner, Lidia Strigari, Tzu-Chen Yen, Roger W. Howell
    Journal of the ICRU 2021 21 1
  • PSMA-Targeting Imaging and Theranostic Agents—Current Status and Future Perspective
    Sashi Debnath, Ning Zhou, Mark McLaughlin, Samuel Rice, Anil K. Pillai, Guiyang Hao, Xiankai Sun
    International Journal of Molecular Sciences 2022 23 3
  • Feasibility of Single-Time-Point Dosimetry for Radiopharmaceutical Therapies
    Xinchi Hou, Julia Brosch, Carlos Uribe, Alessandro Desy, Guido Böning, Jean-Mathieu Beauregard, Anna Celler, Arman Rahmim
    Journal of Nuclear Medicine 2021 62 7
  • A Novel Time–Activity Information-Sharing Approach Using Nonlinear Mixed Models for Patient-Specific Dosimetry with Reduced Imaging Time Points: Application in SPECT/CT After 177Lu-DOTATATE
    Theresa P. Devasia, Yuni K. Dewaraja, Kirk A. Frey, Ka Kit Wong, Matthew J. Schipper
    Journal of Nuclear Medicine 2021 62 8
  • Advances in 177Lu-PSMA and 225Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
    Sui Wai Ling, Erik de Blois, Eline Hooijman, Astrid van der Veldt, Tessa Brabander
    Pharmaceutics 2022 14 10
  • Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose
    Courtney Lawhn-Heath, Thomas A Hope, Juana Martinez, Edward K Fung, Jaehoon Shin, Youngho Seo, Robert R Flavell
    The Lancet Oncology 2022 23 2
  • Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
    Andreas Rinscheid, Peter Kletting, Matthias Eiber, Ambros J. Beer, Gerhard Glatting
    EJNMMI Physics 2020 7 1

Article usage

Article usage: December 2019 to April 2025

AbstractFullPdf
Dec 2019439089
Jan 2020153038
Feb 2020126021
Mar 2020122019
Apr 2020123017
May 202090017
Jun 202068043
Jul 2020144023176
Aug 202062334123
Sep 20202323072
Oct 20202623287
Nov 20201671352
Dec 20201882162
Jan 2021527583
Feb 2021636070
Mar 20215193107
Apr 2021617295
May 2021577281
Jun 20214110977
Jul 2021269076
Aug 20213111164
Sep 2021439267
Oct 202131120101
Nov 2021458973
Dec 2021398582
Jan 2022378254
Feb 20224610283
Mar 20224512889
Apr 202246105100
May 20224317695
Jun 20222416087
Jul 2022219871
Aug 2022207678
Sep 2022169644
Oct 20221884257
Nov 2022199453
Dec 2022149365
Jan 20233210873
Feb 20232811569
Mar 2023389985
Apr 2023219068
May 2023197463
Jun 20232310854
Jul 202397748
Aug 2023278357
Sep 2023154828
Oct 2023196057
Nov 20237811767
Dec 20231710955
Jan 20244315474
Feb 2024489355
Mar 20243987100
Apr 20243020595
May 20242211758
Jun 2024239651
Jul 20242711081
Aug 20242613559
Sep 20243112468
Oct 20242410768
Nov 20242612052
Dec 20241311451
Jan 20252110785
Feb 20252420142
Mar 20251716353
Apr 20252718681
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 66 (5)
Journal of Nuclear Medicine
Vol. 66, Issue 5
May 1, 2025
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Radiation Dosimetry in 177Lu-PSMA-617 Therapy Using a Single Post-treatment SPECT/CT: A Novel Methodology to Generate Time- and Tissue-specific Dose Factors
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Radiation Dosimetry in 177Lu-PSMA-617 Therapy Using a Single Post-treatment SPECT/CT: A Novel Methodology to Generate Time- and Tissue-specific Dose Factors
Price A Jackson, Michael S Hofman, Rodney J. Hicks, Mark Scalzo, John A Violet
Journal of Nuclear Medicine Dec 2019, jnumed.119.233411; DOI: 10.2967/jnumed.119.233411

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Radiation Dosimetry in 177Lu-PSMA-617 Therapy Using a Single Post-treatment SPECT/CT: A Novel Methodology to Generate Time- and Tissue-specific Dose Factors
Price A Jackson, Michael S Hofman, Rodney J. Hicks, Mark Scalzo, John A Violet
Journal of Nuclear Medicine Dec 2019, jnumed.119.233411; DOI: 10.2967/jnumed.119.233411
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • Will SPECT/CT Cameras Soon Be Able to Display Absorbed Doses? Dosimetry from Single-Activity-Concentration Measurements
  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Characterization of Effective Half-Life for Instant Single-Time-Point Dosimetry Using Machine Learning
  • Clinical Trial Protocol for LuCAB: A Phase I-II Trial Evaluating Cabazitaxel in Combination with [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer
  • SPECT Deserves RESPECT: The Potential of SPECT/CT to Optimize Patient Outcomes with Theranostics Therapy
  • Impact of Posttreatment SPECT/CT on Patient Management During 177Lu-PSMA-617 Radiopharmaceutical Therapy
  • First-Strike Rapid Predictive Dosimetry and Dose Response for 177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
  • Dosimetry of [177Lu]Lu-PSMA-Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Metaanalysis
  • Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [161Tb]Tb-PSMA-I&T
  • Impact of the Reference Multiple-Time-Point Dosimetry Protocol on the Validity of Single-Time-Point Dosimetry for [177Lu]Lu-PSMA-I&T Therapy
  • Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection
  • Rethinking Dosimetry: The Perils of Extrapolated External-Beam Radiotherapy Constraints to Radionuclide Therapy
  • Impact of Single-Time-Point Estimates of 177Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles
  • Single-Time-Point Imaging for Dosimetry After [177Lu]Lu-DOTATATE: Accuracy of Existing Methods and Novel Data-Driven Models for Reducing Sensitivity to Time-Point Selection
  • Toward Single-Time-Point Image-Based Dosimetry of 177Lu-PSMA-617 Therapy
  • Evaluation of 177Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)
  • Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA I&T and 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry
  • Thoughts on "Tumor Sink Effect in 68Ga-PSMA-11 PET: Myth or Reality?"
  • Reply: Single-Time-Point Tumor Dosimetry Assuming Normal Distribution of Tumor Kinetics
  • Kidney Doses in 177Lu-Based Radioligand Therapy in Prostate Cancer: Is Dose Estimation Based on Reduced Dosimetry Measurements Feasible?
  • Reimbursement Approaches for Radiopharmaceutical Dosimetry: Current Status and Future Opportunities
  • Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice
  • A Novel Time-Activity Information-Sharing Approach Using Nonlinear Mixed Models for Patient-Specific Dosimetry with Reduced Imaging Time Points: Application in SPECT/CT After 177Lu-DOTATATE
  • Feasibility of Single-Time-Point Dosimetry for Radiopharmaceutical Therapies
  • Will SPECT/CT Cameras Soon Be Able to Display Absorbed Doses? Dosimetry from Single-Activity-Concentration Measurements
  • Google Scholar

More in this TOC Section

Theranostics

  • Can 177Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data
  • Determination of the Intralesional Distribution of Theranostic 124I-Omburtamab Convection-Enhanced Delivery in Treatment of Diffuse Intrinsic Pontine Glioma
  • Evidence-Based Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data
Show more Theranostics

Clinical (Radiobiology/Dosimetry/Safety)

  • Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns
  • Dosimetry for Radiopharmaceutical Therapy: Current Practices and Commercial Resources
Show more Clinical (Radiobiology/Dosimetry/Safety)

Similar Articles

Keywords

  • Image Processing
  • radiobiology/dosimetry
  • radionuclide therapy
  • dosimetry
  • Lu-PSMA-617
  • prostate cancer
SNMMI

© 2025 SNMMI

Powered by HighWire